RecruitingPhase 1NCT07401121

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

Koanewa: A First in Human, Phase 1b, Open-label, Non-randomised, Single Dose Study to Assess the Safety and Tolerability of CTx1000 in Participants Diagnosed With Amyotrophic Lateral Sclerosis

Sponsor

Celosia Therapeutics Pty Ltd

Enrollment

15 participants

Start Date

Jan 12, 2026

Study Type

INTERVENTIONAL

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Summary

This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AAV9 Gene therapy for people with als (amyotrophic lateral sclerosis). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAAV9 Gene therapy

Single dose gene therapy

Locations(1)

Macquarie University Hospital

Sydney, New South Wales, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07401121

Related Trials

Tofersen in Non-SOD1 ALS

NCT072941442 locations

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

NCT075433675 locations